42.71
42.71 (0%)
As of Apr 25, 2025
Monopar Therapeutics [MNPR]
Source:
Company Overview
Monopar Therapeutics Inc is a clinical-stage biopharma company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology.
| Country | United States |
| Headquarters | wilmette, illinois |
| Phone Number | ( 847 ) 388-0349 |
| Industry | manufacturing |
| CEO | Chandler D. Robinson |
| Website | www.monopartx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-16.2 |
| Net Income | $-15.6 |
| Net Cash | $38.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -46.1% |
| Profit as % of Stockholder Equity | -28.3% |
Management Effectiveness
| Return on Equity | -28.3% |
| Return on Assets | -25.9% |
| Turnover Ratio | |
| EBITA | $-16.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $60.3 |
| Total Liabilities | $5.3 |
| Operating Cash Flow | $-6.4 |
| Investing Cash Flow | $-14.3 |
| Financing Cash Flow | $59.3 |
